Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...

Anant Madabhushi, PhD, executive director for the Emory Empathetic AI for Health Institute, discusses the potential of ...

Japan's MHLW has accepted for review GSK's NDA for Blenrep for patients with relapsed or refractory multiple myeloma.

A father and his doctor are set to cycle 450km to Paris to help fund a cure. Richard Sadler was diagnosed with myeloma, an incurable blood cancer, in 2021. On Thursday, September 26, the 61-year-old ...

The Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with newly diagnosed ...

"Myeloma is a dangerous disease. According to statistics, only about a third of patients live longer than five years. Without ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

US FDA approves anti-CD38 therapy, Sarclisa in combo with standard-of-care treatment for adult patients with NDMM who are not eligible for transplant: Paris Tuesday, September 24, ...

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...

The Food and Drug Administration has approved Sarclisa as a first-line treatment for patients with multiple myeloma who are ...